Related Experiment Video
Updated: Jul 9, 2025
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Identification of repurposable drug targets in Mycoplasma pneumoniae using subtractive genomics, molecular docking
Zeshan Mahmud Chowdhury1, Tabassum Binte Jamal1, Ishtiaque Ahammad1
1Bioinformatics Division, National Institute of Biotechnology, Ganakbari, Ashulia, Savar, Dhaka, 1349, Bangladesh.
Abstract:
Mycoplasma pneumoniae is a significant causative agent of community-acquired pneumonia, causing acute inflammation in the upper and lower respiratory tract as well as extrapulmonary syndromes. In particular, the elderly and infants are at greater risk of developing severe, life-threatening pneumonia caused by M. pneumoniae. Yet, the global increase in antimicrobial resistance against antibiotics for the treatment of M. pneumoniae infection highlights the urgent need to explore novel drug targets. To this end, bioinformatics approaches, such as subtractive genomics, can be employed to identify specific metabolic pathways and essential proteins unique to the pathogen that could be potential targets for new drugs. In this study, we implemented a subtractive genomics approach to identify 61 metabolic pathways and 42 essential proteins that are unique to M. pneumoniae. A subsequent screening in the DrugBank database revealed three druggable proteins with similarity to FDA-approved small-molecule drugs, and finally, the compound CHEBI:97093 was identified as a promising novel putative drug target. These findings can provide crucial insights for the development of highly effective drugs that selectively inhibit the pathogen-specific metabolic pathways, leading to better management and treatment of M. pneumoniae infections.
Insights
Researchers identified novel drug targets for Mycoplasma pneumoniae, a cause of severe pneumonia. Subtractive genomics revealed unique pathogen proteins and pathways, leading to a potential new drug candidate to combat antimicrobial resistance.
Area of Science:
- Microbiology
- Bioinformatics
- Drug Discovery
Background:
- Mycoplasma pneumoniae causes severe pneumonia, particularly in vulnerable populations.
- Increasing antimicrobial resistance necessitates new therapeutic strategies.
- Targeting pathogen-specific pathways offers a route to novel drug development.
Purpose of the Study:
- To identify unique metabolic pathways and essential proteins of Mycoplasma pneumoniae using subtractive genomics.
- To screen for druggable targets within the identified unique components.
- To discover novel drug candidates for treating M. pneumoniae infections.
Main Methods:
- Subtractive genomics approach to identify Mycoplasma pneumoniae-specific targets.
- Bioinformatic analysis of metabolic pathways and essential proteins.
- Screening of identified targets against the DrugBank database.
Main Results:
- Identified 61 unique metabolic pathways and 42 essential proteins specific to Mycoplasma pneumoniae.
- Discovered three druggable proteins with potential therapeutic relevance.
- Identified CHEBI:97093 as a promising novel drug target candidate.
Conclusions:
- Subtractive genomics is effective for identifying pathogen-specific drug targets.
- Novel drug targets for Mycoplasma pneumoniae have been identified.
- These findings support the development of new treatments against M. pneumoniae infections and antimicrobial resistance.
More Related Videos
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017